TG Therapeutics Inc. (TGTX)

5.37
NASDAQ : Health Technology
Prev Close 5.58
Day Low/High 5.26 / 5.68
52 Wk Low/High 4.95 / 17.35
Avg Volume 1.53M
Exchange NASDAQ
Shares Outstanding 82.82M
Market Cap 462.13M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TG THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In TG Therapeutics, Inc. To Contact The Firm

TG THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In TG Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against TG Therapeutics, Inc.

TGTX LOSS NOTICE: Rosen Law Firm Reminds TG Therapeutics, Inc. Investors Of Important Deadline In Class Action - TGTX

TGTX LOSS NOTICE: Rosen Law Firm Reminds TG Therapeutics, Inc. Investors Of Important Deadline In Class Action - TGTX

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of TG Therapeutics, Inc.

Johnson Fistel Files Class Action Suit Against TG Therapeutics, Inc.

Johnson Fistel Files Class Action Suit Against TG Therapeutics, Inc.

SAN DIEGO, Oct. 12, 2018 /PRNewswire/ -- Johnson Fistel, LLP announces that a class action has been commenced on behalf of purchasers of TG Therapeutics, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against TG Therapeutics, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against TG Therapeutics, Inc.

Federman & Sherwood announces that on October 4, 2018, a class action lawsuit was filed in the United States District Court for the Southern District of New York against TG Therapeutics, Inc.

Scott Scott Attorneys At Law LLP Alerts Investors To Securities Class Action Against TG Therapeutics, Inc. (TGTX)

Scott Scott Attorneys At Law LLP Alerts Investors To Securities Class Action Against TG Therapeutics, Inc. (TGTX)

NEW YORK, Oct. 10, 2018 /PRNewswire/ --  Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against TG Therapeutics, Inc.

INVESTOR ALERT: Ademi & O'Reilly, LLP Reminds Investors In TG Therapeutics, Inc. (TGTX) Of December 3 Deadline

INVESTOR ALERT: Ademi & O'Reilly, LLP Reminds Investors In TG Therapeutics, Inc. (TGTX) Of December 3 Deadline

MILWAUKEE, Oct. 8, 2018 /PRNewswire/ -- Ademi & O'Reilly, LLP announces that a class action lawsuit has been filed against TG Therapeutics, Inc.

TG THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In TG Therapeutics, Inc. To Contact The Firm

TG THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In TG Therapeutics, Inc. To Contact The Firm

NEW YORK, Oct. 5, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against TG Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against TG Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against TG Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of TG Therapeutics, Inc.

Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against TG Therapeutics, Inc.

Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against TG Therapeutics, Inc.

Robbins Geller Rudman & Dowd LLP ( http://www.rgrdlaw.

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against TG Therapeutics, Inc. (TGTX)

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against TG Therapeutics, Inc. (TGTX)

NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against TG Therapeutics, Inc.

TG Therapeutics (TGTX) Alert: Johnson Fistel Investigates TG Therapeutics, Inc.; Investors Encouraged To Contact The Firm

TG Therapeutics (TGTX) Alert: Johnson Fistel Investigates TG Therapeutics, Inc.; Investors Encouraged To Contact The Firm

SAN DIEGO, Sept. 26, 2018 /PRNewswire/ -- Johnson Fistel, LLP, a shareholder rights law firm, is investigating potential claims on behalf of investors of TG Therapeutics, Inc.

Noteworthy Friday Option Activity: TGTX, CIVB, RST

Noteworthy Friday Option Activity: TGTX, CIVB, RST

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in TG Therapeutics Inc , where a total of 29,923 contracts have traded so far, representing approximately 3.0 million underlying shares. That amounts to about 252.7% of TGTX's average daily trading volume over the past month of 1.2 million shares.

First Week Of January 2021 Options Trading For TG Therapeutics (TGTX)

First Week Of January 2021 Options Trading For TG Therapeutics (TGTX)

Investors in TG Therapeutics Inc saw new options become available this week, for the January 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TG Therapeutics Is Now Oversold (TGTX)

TG Therapeutics Is Now Oversold (TGTX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

How I See Biotechs Now

How I See Biotechs Now

I expect deal volume to have a substantial uptick before the end of 2018 rolls around.

First Week Of TGTX October 19th Options Trading

First Week Of TGTX October 19th Options Trading

Investors in TG Therapeutics Inc saw new options begin trading this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new October 19th contracts and identified one put and one call contract of particular interest.

TGTX September 21st Options Begin Trading

TGTX September 21st Options Begin Trading

Investors in TG Therapeutics Inc saw new options begin trading today, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

Notable Two Hundred Day Moving Average Cross - TGTX

Notable Two Hundred Day Moving Average Cross - TGTX

In trading on Wednesday, shares of TG Therapeutics Inc crossed below their 200 day moving average of $11.84, changing hands as low as $11.50 per share. TG Therapeutics Inc shares are currently trading off about 2.7% on the day.

First Week Of July 20th Options Trading For TG Therapeutics (TGTX)

Investors in TG Therapeutics Inc saw new options become available this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

Relative Strength Alert For TG Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of June 15th Options Trading For TG Therapeutics (TGTX)

Investors in TG Therapeutics Inc saw new options begin trading this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

TG Therapeutics, Inc. To Present At The Needham 17th Annual Healthcare Conference

TG Therapeutics, Inc. To Present At The Needham 17th Annual Healthcare Conference

Presentation scheduled for Wednesday, March 28, 2018 at 4:00pm ET

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

TG Therapeutics, Inc. Announces Fourth Quarter And Year-End 2017 Financial Results And Business Update

TG Therapeutics, Inc. Announces Fourth Quarter And Year-End 2017 Financial Results And Business Update

Investor conference call to be held today, Thursday March 8, 2018 at 8:30am ET  

TG Therapeutics, Inc. To Host Conference Call On Fourth Quarter And Year-End 2017 Financial Results And Business Update

TG Therapeutics, Inc. To Host Conference Call On Fourth Quarter And Year-End 2017 Financial Results And Business Update

Investor Conference Call to be held Thursday, March 8, 2018 at 8:30am ET  

First Week of April 20th Options Trading For TG Therapeutics (TGTX)

First Week of April 20th Options Trading For TG Therapeutics (TGTX)

Investors in TG Therapeutics Inc saw new options become available this week, for the April 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new April 20th contracts and identified one put and one call contract of particular interest.

TheStreet Quant Rating: D- (Sell)